Lakeland Community College biotechnology sciences students getting boost from grant – News-Herald.com

Thanks to a $40,320 grant from the Ohio Department of Higher Education, some hard-working Lakeland Community College biotechnology students will be eligible for scholarships to cover their tuition and fees.

The program is called Choose Ohio First and is aimed at helping students pursuing degrees in science, technology, engineering, mathematics and medicine or STEMM, its associated web page shows.

In Lakelands case, the grant applies to biotechnology science students who meet certain criteria, a media release from the school confirms.

Students who receive this scholarship will have their tuition fully covered at Lakeland, said Joe Deak, chairman of the schools biotechnology science program.

Advertisement

He added that two Lakeland Community College students are now using this funding.

The scholarship covers up to $4,000 in tuition and fees for biotechnology students who dont receive PELL grants, according to Lakelands release.

It goes on to explain that high school graduates who passed chemistry with a C or better are encouraged to apply if they fit the following criteria:

Have an interest in a career in the laboratory biological sciences or data/analysis management as it pertains to biological data

Have a 3.0 overall GPA

Place into college algebra

Reside in Ohio.

Lakelands recent investments in its science and health technology programs and facilities have been making headlines in recent years, especially with the 2015 passage of its capital improvement bond issue, which is being used to fund a $40 million renovation and expansion of the colleges 20-year-old Health Technologies Building, bring the science hallway renovation to completion and help with other infrastructure improvements.

This is the stuff of the future, confirmed Arts & Sciences Division Dean Steven Oluic, who was on hand at a Sept. 1 open house for the renovated, third-floor science wing, when students, teachers, staff and anyone interested could see it, tour the classrooms and labs and learn about all the new, cutting-edge technology there.

I will submit to you that our biology, chemistry and physical science labs are among the best in the area, Oluic said. Really, youd be hard-pressed to find better labs.

College President Morris W. Beverage agreed.

When I went to Lakeland in 1972 and 1973, in the original labs up there, they were new, he said. This is the sort of thing you do every 40 or 50 years and you do it right. And, to do it right, you make sure the equipment and technology the students will be using are the standard of what theyll be using when they leave here. We want our students to experience what theyre going to experience in the world when they move on from here.

For Deak, theres no question thats exactly what Lakelands students are getting.

Deak said that, in his 20 years with the schools program, hes always been able to find grant money to keep it at the cutting edge and, thanks to this latest round of funding, the department is able to offer an unprecedented level of training to students who will likely go on to hit the ground running in roles which may not even exist yet.

Our folks wind up in research and development, quality control and medical lab technology, he said, just naming a few, and he added that the lab in which he answered these questions would pretty much be the envy of anyone at Case Western Reserve or Cleveland State University.

There are numbers to prove it, too.

According to Lakelands statement about the Choose Ohio First grant, Lakelands biotechnology science program has more than a 95 percent placement rate into jobs or transfer to a four-year school.

Institutions where graduates matriculate include Case Western Reserve University, Cleveland State University, Indiana Wesleyan University, John Carroll University, Lake Erie College and Youngstown State University, the statement reads. Lakeland also has a 2+2 articulation with Ursuline College, which allows students to transfer all of their credits and graduate with a bachelors degree in two additional years or less.

Deak said some students are even fortunate enough to land jobs with employers who actually pay their tuition for them.

After graduating from Lakeland, many students are then able to receive tuition waivers or reimbursements from their employers to reduce, or eliminate, the cost of the bachelors degree, he said.

Read more from the original source:
Lakeland Community College biotechnology sciences students getting boost from grant - News-Herald.com

Biotechnology – crbusa.com

Driven to solve your unique challenges.

The biotechnology industry requires sophisticated, mixed-use facilities for product development, manufacturing, and distribution. Effective process-driven engineering coupled with an in-depth understanding of adaptive bioprocess design, and the requirements that impact it, are critical to meeting your unique design needs.

For more than three decades, CRB has specialized in delivering high-quality bioprocess facilities that are safe, reliable, and sustainable. Utilizing state-of-the-art methodologies and practices, we provide services across the entire project lifecycle, from conceptual design through preliminary and detailed design, construction, commissioning, and validation.

Our biotechnology teams are widely acknowledged as some of the top experts in their field.They actively participate in industry committees that help advance the standards andguidelines for biotech facilities and processes. Drawing fromtheunparalleled experience of our team of experts, many of whomhave worked atoperating companies themselves,CRB can provide a deep understanding of clinical, research, and regulatory requirements specific to your facility, as well as the processes that drive your business.

At CRB, we believe every project deserves acustomized approach.We work collaboratively with youtounderstand your needs, andwetailor our world-class expertise to find the right solutions for your technical challenges.Most importantly,we approach your project with the samemindset thatour founders instilled in thiscompany 30+ years ago -- we continually put your interests first. That's why, when partnering with CRB, you can be assured thatyour teamwill never be satisfied untilwe haveachieved success for your business!

Read more:
Biotechnology - crbusa.com

Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI) – The Cerbat Gem


The Cerbat Gem
Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI)
The Cerbat Gem
Puma Biotechnology Inc logo Royal Bank of Canada set a $40.00 target price on Puma Biotechnology Inc (NYSE:PBYI) in a research note published on Wednesday morning. The firm currently has a hold rating on the biopharmaceutical company's stock.
91 institutional investors are raising stakes in Puma Biotechnology ...Post Analyst
The 260,817 Shares in Puma Biotechnology Inc (PBYI) Acquired by ...BangaloreWeekly
Well recognized Stock of Market: Puma Biotechnology, Inc.'s (PBYI ...Hot Stocks Point
Rives Journal
all 6 news articles »

Originally posted here:
Royal Bank of Canada Reiterates $40.00 Price Target for Puma Biotechnology Inc (PBYI) - The Cerbat Gem

Cell-free biotech will make for better products – The Economist

Y[o~P2i#x)- [$$xv&]8Cs#M#wz~ywUYwM:Xi)|zMyb"]LJNf3ETrZw?;T(jJ9RR.z]Vx|[LSgKv.VVKreZ}Q|XHQs`x9(G]-D[ZuxJ7auXSNU^d:HwuigQ>~(MK[mK jJ% KnWOX)MyW,}JaT^EoL1il5bm}Jm*^i({^gWJyFyV*y6=hy%8/uh+L)^.%wfYw._^Gk:GVuu vm.=scL f`~PS] Df114Zdp!4 [U)Ug V/e1T. rR}wn*TiM SOil^Q]OwV OMLa1?S-$5>DK))q|;s=s9w61K, 1G9P8k@JIC$0p8c8r59U0zQEJd9$4*q?YF|w{1#zh<}?#.!P5f~p3;dlr}hvsj9sz"VB};3,w~M-rUcMi+N1AA$CF0,vVq>F/^+I]un%RvL'H/r f8T!`PT:G;Q?&Pgm6X:S5sB{?(>~qwzhs"Az2yNv~oZvx{"kc}rkm3xZeKtf>)visn8WZ,4Qp4$DE>x8Wg_X`-b?nm_w/ =mT[TFtw.#l4S(<73S,uY,%UW8iZ-Xbz%s (d qoZ%gzkv/osK{?" ` f_8_Ow%n^WS8< D*sT[n*[ 4ygY_B{7[,J~918|.OuS.1qW=dw5Hu0nO^:`' ]' Z3 >4&@HR1 1/&4FBLd*6dN%ac<*}a*&V_@ZMoY#< WyKsP+ !chVo[s Kvifmsyg 5VQTm1OJ1n$iDM- )3b]v 2ObdW aM^URavE |Y}qd]/DYzUTphAug]K thSXL_@XeN+Z8_BH$UulQa+Xjq+FLj-"kMy)c_}xM{]bv.$zB$x&HKTlf&@1;.|lTH'#'7*P*Ih_xhlBw.?;J4yP)'~N43(pS4<>Mf'dc#YymNQp/[Du8@RSwCteoquw?0x>`l j?>?MRCEE.DP ^mgOe;hJ7TF+DSC&tR,$b%n6<5jDdE:5-M1xX9}%TQ9~^a{jSg/=Q?%,qJ`.8Ed?D6&?;6j]-+D+9G^F=~hS"3U~pDtTrH< ud#]M0+* 9^dUV]8PwCY Rp$=qzr'!/x998sW;zH.U>zW[^6XwI:g^8GP&} )yi#ZmohD1]H8b]OI? ~Mp /N8wuZUU4E%OsU!IzVj%MZK p!R 5H9,'2/ynybpbN)2TbnhLYp|jk*9*@@I^oJMM+uve.zr4hIhd?pdq4_PmFq4= $1().m'h >Qtwqu$t3W6iI6$|"p &2'zB]'+E9ca?CF7[sl955@50v&zckBrtn;e3Sf7r-f@:E?#|5M W1OM|E~_V?Wl!t1@/;e pfD622]1tg4!Izc7E;{G78'`bO!Jmzn%o'd>Sa~NXD(jWo^SK'k1v=R]?hS#MN$9]%+_<]<57(2Fju"?zfGzsE %{G^ f 5Eni~zF {(R+*6X8 DSUvi?Nnc3"3N|#yON='8B63<,7agE|B7+Ed1fib;i? `W<1!hIrogk]=>ousepkWNb>HxCCF9BOf{rF('SM51WoZ9Z]S,Wv4w~;3I*(ge8E*Vk=I}s8RMKX-}y]C"Ub%I]9mJL+yJcgFWzm8s,qs(I q.g|X^K8cZ(c$KVEs"u9x] `'%?W)dXYjmUT4k#u2S8/~ktAn$H]|?c|oh"3Obo{$)W22(5[lc8fRPvh s_nB_nWE>G;uCEsTtFX)P7 jJ <8@_e+yEToP=y8|sB;_0?_+ dPJ /-A}D4^&=2#iI% Y]x@Pz/K^Radm+XB9%:5.&KW"geCc-,nPh|P*#j'1H56D8F(T(+]??sScby]`I4fx%WA%8Hg8)(T5r~2`qMwE :v*WlW.4:X G U`Y{{$- f'09c+2#EX[EOR/b?~Rzt5-W2VTJ4iwKdpu(Hx?`.iQ} IHqz4g C-)z.A7 jx}PC2mHzF+WV"1@U ^&94yc]dp++|T;*WB#icjg)`(?! ~A+5EZWNN>] m9m+zav3Vn_~`6a_n0$cQ[5^;6YvvF7w4ozO:):Vre5$Tb)3@9W>#:_X)._|D@alWA3W!"t,3a &d%qpxaFoS.pe&oOxQ Z+rW^TP1%A<9p6&~c!kWBmI1!%2"1*/=< j_p Y"[(lXlZw_w19A+%W#$nfTJO5r5d#0_-tu^`7&kY`riu+Dp kbqHh ]lw4; fE^QFmSlN_F: dt @2rxsV@d6 z^kgkNUJ0JKE@G>*Y*P, s@i7:[.vbqN*gZtz&.3{Hm6q=P6u5uOw3`'_WCt+&$?r%2}fU<|UrQ{e+YLkzpr3.sQTj3L .knOXM5*Km53/L-%.g'!jdO%7 5(F`V CeTFrg :1': -}NM.lzQgR>?g"k3Te-}i_b_9y$y }dt0S^yOb6%;/1m$-M&2){Nuw`b;JI]g'.jW4c>|j]'www44|?GIr6E q^gps>On -/+)j@PC-^-V|{- wv!QZd nwzX(GP(*9i50<8z= fx21 c)y/gTVZEyX-Kr+*e|)P$F!>)lgJOL*v%]KC|e$@%9:;.t"eEARR5A"`u4U[eC"!#EK$hwovs:n fQ;va8X-h;Yw(l8:L0>~L1;DNE4H:fL~-L[5h3BhYl@jkU1/tb~p/Gdw%*V~ N9#@jj(?oe]xqrqs6 *0{l2bO_(NZkOpjpM,G,+}WN v)xfl(Y{^cGjc|[??mSCd5|i='lf3'=h> h?",*rI|9MZZ??VG-QJwt}+jX!dq17KeCH/ Zb+@+/a5?^I^e}K'J~w;W?0!7sGA )tk/y4d_r9A?.6q.[DiQ1xuKjBEKMF"SzbqOIBY[4Agct2aMv;)OT`qbC.,j4Vp'SA3plk!6+1)6-;j dY&LODHV?*BCpndWzn=8f|[Dp.]2m0Tm#-/vN@cNu i#]WR@&6[{+ 5E7pS2&FQ]"R/*M)w6|"9{t]S E?W@=7,nwSW`c,l}>f6f6f;Nn:Y *ieE*@j5l3.aJ@%9=uV^60amdt"%-^jY1Z8>Q:l *CQyPG;J#^28=sf>+=h`b*#(shYf^l W>N>nUqT,&)(NqZtqQT#jD[M]&`~oAOGX.UbT+:Lkc@4w+;l.]z0kD: Rz1R/P> tE]eY ~Rr;HO94X tWJu<8!Inx~d}!DO4hcC]r)>=CCLwfptQ3N7xh$ d%95LD63}/./mf #y2:p9C3)Q

See the original post:
Cell-free biotech will make for better products - The Economist

Plandai Biotechnology Expanding Footprint of Phytofare into U.S. with Continued Sales – Yahoo Finance

NEW YORK, NY--(Marketwired - May 04, 2017) - Planda Biotechnology (PLPL) announced last week that its highly bioavailable Phytofare Catechin Complex would be the active ingredient in Capital Brand's reformulated and soon-to-be released SuperFood Fat Burning Boost, which is used with the well-known brand NutriBullet. This week we learned that thanks to a deal with Coyne Healthcare -- Planda's signature brand Phytofare will make its way to the U.S. and Europe as the star ingredient in Coyne Healthcare's product Origine 8.

Coyne Healthcare placed an order for 1.2 million of Planda's Origine 8 capsules, which is a product that not only uses the highly bioavailable green tea extract, Phytofare Catechin Complex, but further enhances the bioavailability of the extract by using an advanced liposome technology developed and clinically validated to improve the delivery of nutritional substances.

Origine 8 is a product that entraps all 8 of the catechins of the tea plant, and according to Planda, it is the only catechin-based capsule on the market backed by human clinical studies that prove it has superior bioavailability.

Coyne Healthcare has already been selling Planda's unique product in South Africa, but it now expects to launch Origine 8 this month in both the U.S. and Europe. The good news for Planda is that Coyne Healthcare has forecasted sales of 10.6 million Origine 8 capsules in 2017, and Coyne expects sales to further increase to 24 million Origine 8 capsules in 2018.

Coyne makes its products (http://coynehealthcare.co.za/#products) available through pharmacies, health food stores and medical practitioners, so for both NutriBullet and Coyne Healthcare to bring Planda's signature brand to the U.S., investors will have a great opportunity to physically see their investment up close and personal.

Sales at Planda and the recognition that the company is gaining globally, is clearly a response to the efforts made by the new COO, Callum Cottrell-Duffield, well before now. He led the company's sales and marketing team in its effort to grow the brand and expand the company's footprint worldwide after Planda's signature product was available for mass production and ready to market on a much broader scale last year. His work to increase sales and marketing throughout Africa, the United States, Europe, Asia and South America by telling the Planda story, is starting to pay off now in 2017.

And, with brands like NutriBullet and Coyne Healthcare, who both use and market only the highest quality ingredients in their products, advertising the Phytofare name, it shouldn't take long for Planda to grow quite an impressive sales footprint worldwide.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Read More

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

Read more:
Plandai Biotechnology Expanding Footprint of Phytofare into U.S. with Continued Sales - Yahoo Finance

Popular TED Talks explore future of agricultural innovation, biotechnology – Genetic Literacy Project

The well-known TED Talks is a clearinghouse of big thinkers and big ideas, and quite a few of them have focused on agriculture and food production over the years.

Engineering Drought Resistance Jill Farrant, a Professor of molecular and cell biology at University of Cape Town, South Africa, is studying how ancient DNA can be turned on to help important food crops fight off drought. She and colleagues have been studying resurrection plants to achieve this goal. Resurrection plants are those that can undergo extreme drought without water for months or even years. Then when the next rain comes along within 12 to 48 hours the plants green up and start growing again.

Farrants How We Can Make Plants Survive Without Water TED Talk featured her research into how resurrection plants work and if those special characteristics could be transferred into other plants, especially food crops.

Robot Swarms Vijay Kumar, Dean of the University of Pennsylvanias School of Engineering and Applied Science, wowed his TED Talk audience with his presentation titled The Future of Flying Robots. His lab is developing autonomous flying robots that use onboard sensors, cameras, and laser scanners to map the environment it is in and avoid obstacles while navigating.

All agriculture-related TED Talks can be found at ted.com/topics/agriculture.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:TED Talks Take on Agriculture Innovation

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Read the rest here:
Popular TED Talks explore future of agricultural innovation, biotechnology - Genetic Literacy Project

Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem


Barron's
Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Northeast Financial Consultants Inc cut its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 48.1% during the first quarter, according to its most recent disclosure with the Securities and ...
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Beaumont Financial Partners LLCTranscript Daily
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at Vetr Inc.Markets Daily
iShares NASDAQ Biotechnology Index (IBB) Stake Maintained by Barrett Asset Management LLCSports Perspectives
BBNS -Community Financial News -Chaffey Breeze
all 27 news articles »

See original here:
Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Best Master’s Degrees in Biotechnology 2017

Biotechnology is a top-notch field of study that emerged into the scientific world as a result of revolutions in Biology, Chemistry, Informatics, and Engineering. It is considered to be an applied branch of Biology. Biotechnology helps out this old and respectable field of science keep up with the pace of time and remain competitive in the contemporary world.

With a Master in Biotechnology, students will study the use of living organisms and bioprocesses in technology, engineering, medicine, agriculture and results in all kinds of bioproducts, from genetically modified food to serious cutting-edge devices used to carry out gene therapy. Students in Master in Biotechnology programs may also explore bioinformatics, which is the application of statistics and computer science to the field of molecular biology. Bioinformatics is extremely important for contemporary biological and molecular researches because the data amount there grows by geometric progression and it is necessary to have adequate technology to process it. Bioinformatic methods are widely used for mapping and analyzing DNA and protein samples, as well as for the study of genetics and molecular modeling. Biotechnology and Bioinformatics do a great favour to traditional fields of study, refreshing them with new methods of research, which allows their drastic development, and you can make your contribution with a Master in Biotechnology degree.

Find out about various Master in Biotechnology programs by following the links below. Don't hesitate to send the "Request free information" form to come in contact with the relevant person at the school and get even more information about the specific Master in Biotechnology program you are interested in.

Go here to read the rest:
Best Master's Degrees in Biotechnology 2017

Kenyan scientists push for female farmers’ access to biotechnology – Genetic Literacy Project

Dr. Felister Makini, Deputy Director General (crops) at the Kenya Agricultural & Livestock Research Organization (KALRO), noted that African women play a critical role in ensuring food security. She urged the government to make farming easier for them by providing modern tools such as biotechnology. As African women, we are the ones who suffer most whenever drought and food shortages strike, despite the availability of technological solutions to these problems, she said. We need to speak with one voice and advocate for a predictable policy environment. I have children and a family to protect. I cannot advocate for something that I know would affect them she added.

On her part, Prof. Caroline Thoruwa, Chairperson, African Women in Science and Engineering (AWSE), noted that for Africa to advance in agri-biotech, women must be involved. It is time to tell the public about the positive side of biotechnology. We need to raise up the status of women in biotechnology and also encourage women to network in order to achieve the noble goal of sharing their science, she said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:AFRICAN WOMEN IN BIOSCIENCES CALL FOR SUPPORTIVE POLICIES ON BIOTECHNOLOGY

For more background on the Genetic Literacy Project, read GLP on Wikipedia

See the article here:
Kenyan scientists push for female farmers' access to biotechnology - Genetic Literacy Project

20 New Biotechnology Products Debut at INTERPHEX 2017 – TSNN Trade Show News (blog)

By Elizabeth Johnson

Leading pharmaceutical and biotechnology companies chose INTERPHEX 2017 to launch their newest products, with 20 companies debuting new technology at the pharmaceutical and biotechnology industry trade show held March 21-23 at the Jacob K. Javits Convention Center in New York City.

In its 38th year, INTERPHEX offered attendees a mix of content including more than 104 conference education sessions, INTERPHEX Live discussions, hundreds of exhibits and product launches.

The show experienced attendee growth, compared with 2016, and attributes much of that to its robust program.

INTERPHEX offers its customers the opportunity to bring their entire teams and engage in education for everyone, said Melissa Ashley, senior vice president of INTERPHEX.

She continued, Attendance is free to those who register ahead to support the industry and allow companies full teams to experience all that is happening in the industry.

Having grown and evolved from a regional to a national and international event, INTERPHEX selected New York as its home because the city is a gateway that allows people to come from abroad and because there are a lot of customers in the tri-state area.

INTERPHEX is reflective of the industry advancing to the future, with organizers working to ensure the needs of technology companies are on display.

Still, the biotechnology industry is slower to change than some industries because it is heavily regulated, according to Kate Scott McCorriston, director of marketing and technical content for INTERPHEX.

The regulations mean people need to attend to learn about new guidance and regulations, McCorriston explained.

She added, Young professionals need to attend to learn how to manufacture new products within regulations and cost-effectively.

Unique features such as INTERPHEX Live keep attendees engaged.

Unlike standard panels or lectures or even exhibitor-led education, INTERPHEX Live discussions allow participants to ask questions and engage in a direct dialogue with experts, with sessions taking place out in the open and not far from registration, making it easy for people to join the discussions.

In addition, INTERPHEX organizers solicit customer feedback to make sure they are hitting the mark with show programming.

We ask, who do they want more of and what research do they need? Ashley said.

She continued, Then, we put that information together with feedback from our technical advisory board in order to create the best program we can.

In addition to showcasing the latest technology, the show itself uses a lot of technology to provide the best experience for attendees and exhibitors, including online matchmaking tools pre-show so that attendees can customize their experience and understand who they want to target before they arrive.

The show invested in a lead retrieval tool that helps exhibitors really know who they are talking to as well.

We want people to engage, not just walk up and down the aisles and leave, Ashley explained.

The goal of INTERPHEXs show organizers was to reach more attendees using the technology they had available, and it appears they got their wish, with a positive response to those tools.

INTERPHEX is sponsored by the Parenteral Drug Association (PDA) and brings over 11,500 global industry professionals and more than 625 industry-leading suppliers together to Learn it, Experience it, Procure it annually.

INTERPHEX 2018 will take place April 19-21 at the Javits Center.

Read more here:
20 New Biotechnology Products Debut at INTERPHEX 2017 - TSNN Trade Show News (blog)

BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC … – ETF Daily News (blog)

March 31, 2017 9:38am NASDAQ:BBC

From Zacks: After being stressed by the twin attacks of higher drug pricing and increased regulatory scrutiny, the biotech sector has made a strong comeback in the first quarter of 2017.

In fact, BioShares Biotechnology Clinical Trials ETF (BBC Free Report) tops the list of the best performing ETFs of the quarter, with impressive returns of about 27.4%. BBC carries a Zacks ETF Rank of 3 or Hold rating with a High risk outlook.

The surge in the fund was largely driven by cheap valuation, robust earnings results and a slew of positive actions taken by the President. In particular, Trump promised to reduce federal regulations by 7580% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trumps proposed tax reforms and cash repatriation policy are also supporting the rally (read: Top ETF Stories of Q1 from Wall Street).

Apart from these, encouraging industry trends including the possibility of increased M&A activity, an accelerated pace of innovation, promising drug launches, growing importance of biosimilars, cost-cutting efforts, an aging population, expanding insurance coverage, the growing middle class, an insatiable demand for new drugs, and ever-increasing health care spending are fueling growth in the sector.

Lets take a closer look at the fundamentals of BBC and its performance.

BBC in Focus

This fund has a novel approach to biotechnology investing with exposure to companies that are in the clinical trials stage. This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index. BBC is a small cap centric fund, having amassed $24.4 million in its asset base. It charges 85 bps in fees per year from investors and trades in light average daily volume of around 14,000 shares.

Holding 70 stocks in its basket, it is widely spread out across various components with none holding more than 3.34% share. Though almost all the stocks in the funds portfolio delivered strong returns, a few were the real stars that more than doubled their size (read: Hit ETFs & Stocks from the Top Sector of February).

Below we have highlighted those five best-performing stocks in the ETF with their respective positions in the funds basket:

Best Performing Stocks of BBC

Esperion Therapeutics Inc. (ESPR Free Report) : The stock has surged about 185% so far this year and carries a Zacks Rank #3 with solid Industry rank in the top 39%. Most of the gains came on hopes of the Food and Drug Administrations (FDA) approval to the cholesterol-lowering medicine bempadoic acid. However, Esperion saw its earnings estimates deteriorating from a loss of $3.46 to a loss of $6.27 for this year over the past 90 days. It also has an unfavorable VGM Style Score of F. ESPR occupies the top spot in the funds basket with 3.3% of the total assets (see: all the Health care ETFs here).

Global Blood Therapeutics Inc. (GBT Free Report) : This stock takes the second position in the funds basket with 2.8% allocation. It has also delivered incredible returns of 169% in the first quarter on rumors of the takeover of a big pharma name like Novo Nordisk (NVO). The stock saw its earnings estimates moving from a loss of $2.89 to a loss of $2.83 for this year over last the 90 days. Further, it belong to a solid Industry with a Zacks Rank in the top 43%. The stock has a Zacks Rank #3 with a VGM Style Score of F.

TG Therapeutics Inc. (TGTX Free Report) : It currently has a Zacks Rank #3 with a VGM Style Score of F. The stock soared nearly 150% in the first quarter with most upside coming after positive study results from its phase 3 clinical trial of treatment for high-risk leukemia patients. However, TG Therapeutics saw negative earnings estimate revision of a nickel for the current year over the past 30 days and has an ugly Zacks Industry rank in the bottom 32%. The stock is the third firm and accounts for 2.7% share in BBC (read: Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs).

Cara Therapeutics Inc. (CARA Free Report) : The stock has been climbing since the start of the year and has gained about 105.5% this quarter on the pending trial results of its lead drug candidate. It hit a new one-year high of $20.90 in the last trading session after the company announced positive results from part A of a phase 2/3 trial for chronic kidney disease-associated pruritus. Cara Therapeutics has a solid Zacks Industry rank in the top 43%. However, it has a Zacks Rank #4 (Sell) with a VGM Style Score of F. The stock occupies the fourth position in the funds portfolio, making up for 2.5% share.

NewLink Genetics Corporation (NLNK Free Report) : This stock takes the seventh spot in the funds basket with 2.2% of assets. It has doubled this quarter but saw negative earnings estimate revision of $1.21 for this year over the past 90 days. NewLink Genetics currently has a Zacks Rank #3 with a VGM Style Score of F and solid Zacks Industry rank in the top 43%.

The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) was unchanged in premarket trading Friday. Year-to-date, BBC has gained 25.75%, versus a 5.59% rise in the benchmark S&P 500 index during the same period.

BBC currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #23 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Zacks Research.

Tags: biotech Equity Health Care NASDAQ:BBC Zacks

Categories: NASDAQ:BBC

Read the original here:
BioShares Biotechnology Clinical Trials Fund(NASDAQ:BBC ... - ETF Daily News (blog)

Company Spotlight: Cellect Biotechnology – RTTNews – RTT News

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Read this article:
Company Spotlight: Cellect Biotechnology - RTTNews - RTT News

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Gains are … – StockNewsUnion

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares have been up over 80% on large volumes. PRAN closed yesterday at $2.48, gapped up to open at $2.95, reached an inter-day high of $4.58, and are now trading around $3.60 for an inter-day gain of over 45%. The nano-cap Australian-based biotech firm has, prior to todays action, an average daily trading volume of just over 59,000 but, by 10:30 AM EST, PRAN shares had already traded over 7.1 million times. A review of news services reveals that no news has been reported by the company or an analyst that could account for todays price action.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a clinical stage biotechnology firm that develops therapeutic medicines. Prana has developed PBT-2 for the treatment of Alzheimers disease. PBT-2 is currently in a Phase IIa clinical trial. Pranas PBT-2 is also being investigated for applications involving other therapeutic applications including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases.

When PRAN is adjusted for dilutive effects, the shares high came in early 2014 when PRAN was trading near $80/share. However, by the end of 2014, PRAN shares would end up down over 74%. Dilution, EPS losses, and weak sales figures have plagued the shares. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) have reported sales of $100,000 every year since 2012 except for 2014 when the company reported a figure of $300,000. EPS losses have been noteworthy. In 2012 the EPS loss for shares holders of PRAN was -$5.00, followed by annual EPS losses of-$6.31, -$8.55, -$3.21, and -$3.98 in 2016. There has also been consistent dilution for PRN shareholders. In 2012 the number of outstanding shares was 800,000 and that number grew annually and in 2016 the number was 1.48 million. Given Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) market cap of only $23 million and its lack of sales, no analysts have reviewed the companys share ratings since 2014.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant. View all posts by Marcus Anderson

Excerpt from:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Gains are ... - StockNewsUnion

German and UK researchers cut time to sepsis diagnosis – European Biotechnology

Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.

In theJournal of Molecular Diagnostics, a research team led by Kai Sohn from Fraunhofer IGB (Stuttgart, Germany) describes the new real-time NGS-based technique that allows an accurate diagnosis of sepsis-causing agents within a few hours of drawing blood. Current diagnostic tests are culture- or PCR-based, which are neither fast nor specific enough to provide timely, critically important information.

"With up to 50 million incident sepsis cases and 11 million sepsis-related deaths per year, sepsis represents a major cause of dealth," explained co-lead-investigator Thorsten Brenner, MD, vice head of the Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany. "Reliable and early identification of the pathogen enables rapid and the most appropriate antibiotic intervention, thereby increasing the chance of better outcomes and patient survival. Currently, standard-of-care diagnostics still rely on microbiological culturing of the respective pathogens, which rarely provide timely positive results."

The investigators described a system that utilized NGS of microbial cell-free DNA to detect blood pathogens within 28 hours. However, their ultimate goal was to develop an even faster test to expedite treatment. To overcome this limitation the investigators established a diagnostic workflow based on 3rd generation nanopore sequencing of microbial DNA. Normally, nanopore sequencing is used to analyze long fragments in sufficient amounts. However, microbial cell-free DNA occurs in small fragments and low quantities in plasma. Nanopore sequencing offers the possibility of real-time analyses during sequencing, which dramatically reduces the time needed to obtain results. "We also had to create validated, specifically adapted bioinformatic procedures to reliably identify pathogens," noted Sohn.

This new technique relies on the use of the handheld nanopore sequencer MinION developed by Oxford Nanopore Technologies. According to the company, the handheld sequencer can read out ultra-long reads, and immediately processes reads in real time.

In their pilot study, the investigators analysed plasma from four septic patients and three healthy controls who were hospitalized in the intensive care unit (ICU). Each sample's DNA underwent sequencing using both technologies: the standard NGS (from world market NGS leader Illumina, which finished a MinION partnership) and the nanopore NGS technology. With nanopore sequencing, all septic patient samples were found to be positive for relevant pathogens, whether bacterial, viral, or fungal.

After additional refinements, the new technique was able to achieve a 3.5-fold increase in sequencing throughput, allowing pathogen identification within minutes after sequencing began. In fact, the highest quality results were generated within 2 or 3 hours of the beginning of sequencing. In contrast, with Illumina the final results are available only after the sequencing is finished. "This new system might facilitate same-shift adaption of antibiotic intervention at the ICU, which might, in turn, improve patient outcomes significantly,"suggested Sohn. In an additional retrospective analysis of 239 samples taken from sepsis patients, however, the accuracy of nanopore sequencing was lower than with Illumina (85% vs. 99%).

"Time consuming, error- and contamination-prone blood cultures are still considered as the standard of care for sepsis diagnostics, frequently leading to an inappropriate and delayed targeted therapy," said Prof. Dr. Brenner. "The nanopore sequencing platform sequences in real time and has the potential to reduce time to diagnosis to only a few hours."

As with every DNA-based method, however, researchers are only able to get information about antibiotic resistance genes, that is which antibiotics won't be effective. To know which antibiotics actually are effective they'd need confirmatory culture-based methods.

See the original post here:
German and UK researchers cut time to sepsis diagnosis - European Biotechnology

India amongst the elite 12 biotechnology destinations in the world – Medical Herald

Today, 26th February 2020, New Delhi is celebrating its 34th Foundation Day at the National Institute of Immunology (NII), New Delhi. Despite the economic slump of 2013-14, Indian industries related to biotechnologies have seen a constant rise, factoring to increasing foreign investment, lucrative and supportive government policies, the surge in demand for the Indian products and a skilled workforce. Compassionate private sector policies coupled with the government measures have seen a rapid growth amounting to an annual growth rate of nearly 20%, thus making India among the top 12 biotechnology destinations in the world.

It is the increasing demand for biotechnology products and services throughout the world that has been the hinge for setting a determined target of US$150 billion by 2025. Indias biotechnology manufacturing is in a boundless position to changeover to bio-economy. This will allow India to re-establish foundations describing the effectiveness of prevailing segments, providing them with a promising setting to operate and grow. The nation has the crucial elements for success, including:

Reenita Das, Sullivan Partner, and Transformational Health Senior Vice President explained Indian biotechnology experts promote the formation of new businesses from pharmaceutical research, medical technology, healthcare IT and healthcare service improvements. Additionally, Indias foreign trade policies and international relations help the biotechnology industry to grow and seek investors or traders globally.

See the rest here:
India amongst the elite 12 biotechnology destinations in the world - Medical Herald

Puma Biotechnology, Inc. Just Released Its Yearly Earnings: Here’s What Analysts Think – Yahoo Finance

Shareholders of Puma Biotechnology, Inc. (NASDAQ:PBYI) will be pleased this week, given that the stock price is up 11% to US$13.60 following its latest yearly results. The statutory results were mixed overall, with revenues of US$272m in line with analyst forecasts, but losses of US$1.95 per share, some 6.2% larger than analysts were predicting. Following the result, analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see analysts' latest (statutory) post-earnings forecasts for next year.

View our latest analysis for Puma Biotechnology

NasdaqGS:PBYI Past and Future Earnings, February 23rd 2020

Taking into account the latest results, the eight analysts covering Puma Biotechnology provided consensus estimates of US$253.4m revenue in 2020, which would reflect a perceptible 6.9% decline on its sales over the past 12 months. Statutory losses are expected to increase substantially, hitting US$1.59. per share. Before this earnings announcement, analysts had been forecasting revenues of US$260.9m and losses of US$1.54 per share in 2020. While revenue forecasts have been revised downwards, analysts look to have become more optimistic on the company's earnings power, given the to earnings per share forecasts.

The average analyst price target was broadly unchanged at US$12.33, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Puma Biotechnology at US$17.00 per share, while the most bearish prices it at US$6.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

In addition, we can look to Puma Biotechnology's past performance and see whether business is expected to improve, and if the company is expected to perform better than wider market. We would highlight that sales are expected to reverse, with the forecast 6.9% revenue decline a notable change from historical growth of 8.5% over the last year. By contrast, our data suggests that other companies (with analyst coverage) in the same market are forecast to see their revenue grow 17% annually for the foreseeable future. It's pretty clear that Puma Biotechnology's revenues are expected to perform substantially worse than the wider market.

The most important thing to take away is that analysts reduced their loss per share estimates for next year, perhaps highlighting increased optimism around Puma Biotechnology's prospects. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider market. The consensus price target held steady at US$12.33, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have forecasts for Puma Biotechnology going out to 2024, and you can see them free on our platform here.

Story continues

We also provide an overview of the Puma Biotechnology Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read the original post:
Puma Biotechnology, Inc. Just Released Its Yearly Earnings: Here's What Analysts Think - Yahoo Finance

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts…

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

See the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service – Yahoo Finance

MIRAMAR, Fla., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) is pleased to announce that the companys subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has begun shipping Excellagen to the Indian Health Services in Arizona, following approval by the value added committee (VAC). Native American Indian adults are almost three times more likely to have diabetes and 2.5 times more likely to die from the complications of diabetes than the majority of other Americans. Excellagen wound conforming gel matrix is FDA cleared to manage 17 types of wounds including diabetic foot ulcers and venous leg ulcers, which are prevalent in the diabetic patient population. The Indian Health Service (IHS), an agency within the U.S. Department of Health and Human Services, provides care to over 2.2 million Native Americans in more than 560 recognized tribes across the country.

Anthony J. Dolisi, President and Chief Executive Officer of Olaregen said, We are excited that Excellagen has been approved by the Indian Health Services Value Added Committee, which not only enables us to begin selling Excellagen in Arizona, but which also opens the door to VAC approval across the IHS. We continue to make gains in the VA hospitals, where Excellagen is achieving some fantastic results for veterans who are dealing with hard to heal wounds, and we expect to achieve a national footprint by the end of the year. Additionally, we have begun the VAC approval process in the private sector and have just signed a new hospital in Texas.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization and medical device companies with new and approved products.

About Olaregen TherapeutixOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care.Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications.Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex's mission is to become a significant force in regenerative medicine and advance the science of healing.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Story continues

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Follow this link:
Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service - Yahoo Finance

Getinge to Acquire Applikon Biotechnology B.V., A Leading Company in the Fast Growing Area of Bioreactor Systems – Yahoo Finance

GOTHENBURG, Sweden, Dec. 19, 2019 /PRNewswire/ -- Getinge announces today an agreement to acquire 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V. Applikon Biotechnology B.V. is a leading company in the fast growing area of advanced bioreactor systems for biopharmaceutical production and research, with an annual net sales of approximately SEK 450 M.

"Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which will be a positive addition to Getinge's existing offer towards the biopharma segment, the fastest growing area within Life Science," says Mattias Perjos, President & CEO Getinge. "This deal further broadens our position within solutions for efficient, safe and contamination-free research and production processes."

Applikon Biotechnology B.V. is leading in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as wellasenzymes and bio-plasticsfor industrial biotechnology. The value of the global bioreactor market is estimated to be SEK 10 B with an expected growth rate 2019-2024 of approximately 10% per year. Applikon Biotechnology B.V. is a privately-held company, founded in 1973 and has its head office in Delft, The Netherlands. The company employs approximately 180 employees worldwide and works mainly through a global distribution network.

"Through Applikon Biotechnology B.V., Getinge will be able to offer customers better solutions and knowledge covering the entire process frominitial screening to full-scale production, using a fully scalable platform," says Arthur Oudshoorn, CEO of Applikon Biotechnology B.V.. "Getinge's global footprint will substantially strengthen our access to the market and further accelerate Applikon's growth."

Getinge will acquire all outstanding shares in Applikon Biotechnology B.V. and will pay approximately SEK 840 M (EUR 80 M) in cash on closing for 100 % of the shares. In addition, a maximum earn out of approximately SEK 630 M (EUR 60 M) can be paid out in 2021-2022 if agreed earnings performance is achieved in 2020-2021. The acquisition will be financed through debt and the net debt to EBITDA ratio is expected to be impacted by 0.2x at closing of deal in the first quarter of 2020. The integration will be stepwise with full effect from 2022. Getinge expects no material integration costs in 2020-2021.

Long-term, Applikon Biotechnology B.V. is expected to bring a material contribution to Getinge's Life Science business area in terms of net sales and EBITA. Getinge's Life Science business performed SEK 2.3 B in net sales and SEK 293 M in EBITA Q4 2018-Q3 2019. For Getinge, the acquisition is not expected to have a material impact on operating profit and earnings per share as of 2020. The acquisition broadens Getinge's position further within solutions for efficient, safe and contamination-free research and production processes in the biopharma segment.

The transaction is subject to, and conditional upon, the employee consultation obligations under the Works Council Act (Wet op de ondernemingsraden) and the SER Merger Code (SER-besluit Fusiegedragsregels 2015) in the Netherlands having been completed and closing is conditional upon customary closing conditions. The deal is expected to be finalized in the first quarter of 2020.

Deutsche Bank is Getinge's exclusive financial advisor in the acquisition process and the committed debt financing for the transaction is provided by SEB. NautaDutilh is Getinge's leading legal advisor in the transaction.

For more information about Applikon Biotechnology B.V.: http://www.applikon-biotechnology.com

Getinge invites to a conference call

Getinge invites to a conference call hosted by Getinge's President & CEO Mattias Perjos and CFO Lars Sandstrm on December 19, 2019, at 12:00 CET. Please see dial in details below to join the conference:

SE: +46-8-566-426-51UK +44-333-300-0804US +1-855-857-0686

Pin code: 44859140#

During the telephone conference a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/2019-dec-press-conference

Alternatively, use the following link to download the presentation: https://www.getinge.com/int/about-us/investors/reports-presentations.

Story continues

This information is information that Getinge AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET on December 19, 2019.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

Media contact:Lars Mattson, Head of Investor RelationsTel: +46-(0)10-335-0043Email: lars.mattsson@getinge.com

Jeanette Hedn Carlsson, EVP Communication & AcademyTel: +46-(0)10-335-1003Email: jeanette.hedencarlsson@getinge.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-to-acquire-applikon-biotechnology-b-v--a-leading-company-in-the-fast-growing-area-of-bioreac,c2995282

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/getinge-to-acquire-applikon-biotechnology-bv-a-leading-company-in-the-fast-growing-area-of-bioreactor-systems-300977468.html

SOURCE Getinge

Excerpt from:
Getinge to Acquire Applikon Biotechnology B.V., A Leading Company in the Fast Growing Area of Bioreactor Systems - Yahoo Finance

Bellerophon Therapeutics Inc (NASDAQ:BLPH) Given Consensus Recommendation of Strong Buy by Brokerages – Riverton Roll

Bellerophon Therapeutics Inc (NASDAQ:BLPH) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus price target of $2.75 for the company and are predicting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned Bellerophon Therapeutics an industry rank of 83 out of 255 based on the ratings given to related companies.

Several analysts recently issued reports on the company. Maxim Group reissued a buy rating and set a $2.00 target price on shares of Bellerophon Therapeutics in a research note on Thursday, November 7th. HC Wainwright reaffirmed a buy rating and set a $3.00 price objective on shares of Bellerophon Therapeutics in a report on Wednesday, December 18th. Finally, ValuEngine raised shares of Bellerophon Therapeutics from a sell rating to a hold rating in a report on Thursday, December 12th.

Shares of BLPH stock opened at $0.35 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.96 and a quick ratio of 1.96. Bellerophon Therapeutics has a one year low of $0.31 and a one year high of $0.79. The companys fifty day moving average price is $0.36 and its 200-day moving average price is $0.49. The company has a market capitalization of $24.10 million, a price-to-earnings ratio of -2.34 and a beta of -0.11.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.01. Equities research analysts expect that Bellerophon Therapeutics will post -0.23 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Bellerophon Therapeutics by 15.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology companys stock valued at $690,000 after purchasing an additional 158,000 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 8.9% in the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology companys stock worth $860,000 after purchasing an additional 116,862 shares during the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Bellerophon Therapeutics by 22.1% in the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology companys stock worth $78,000 after purchasing an additional 23,650 shares during the last quarter. Institutional investors and hedge funds own 50.54% of the companys stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Featured Article: Google Finance Portfolio

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
Bellerophon Therapeutics Inc (NASDAQ:BLPH) Given Consensus Recommendation of Strong Buy by Brokerages - Riverton Roll